• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Forensic Exam Shows Pattern in 4 Deaths of Sanofi Dengue Vaccine Recipients

biospaceJanuary 11, 2018

Tag: Sanofi , Dengue

Forensic examination conducted on 4 children who received a controversial dengue vaccine indicated a "pattern" that led to their deaths, the Public Attorney's Office said Wednesday. 

The Philippines late last year halted the vaccination of public school students with the vaccine Dengvaxia after French drug maker Sanofi disclosed that it might increase the risk of severe dengue in recipients not previously infected by the mosquito-borne virus.

Dr. Erwin Erfe, head of the PAO Forensic Laboratory, said the 4 children they examined contracted dengue 6 months after receiving the vaccine.

Previous:Nestle Emerges as the Frontrunner for Merck KGaA's $5B Consumer Health Biz

Next:Can 2018 Possibly Rival 2017's Biotechs Record Venture Capital Splurge?

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Forensic Exam Shows Pattern in 4 Deaths of Sanofi Dengue Vaccine Recipients | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Dengue IgG-IgM (HFRS) Rapid Test

Dengue IgG-IgM (HFRS) Rapid Test
Dengue NS1 Antigen and IgG/IgM Duo Panel Test

Dengue NS1 Antigen and IgG/IgM Duo Panel Test
Dengue (lgM&lgG) test cassette

Dengue (lgM&lgG) test cassette
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins
CEFIXIME cephalosporins

CEFIXIME cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service